metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Incidencia de bacteriemia en grupos histológicos de neoplasias hematológicas
Información de la revista
Vol. 21. Núm. 1.
Páginas 24-29 (enero 2003)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 21. Núm. 1.
Páginas 24-29 (enero 2003)
Acceso a texto completo
Incidencia de bacteriemia en grupos histológicos de neoplasias hematológicas
Visitas
5573
Ramón Teiraa,1
Autor para correspondencia
rteira@hbas.osakidetza.net

Correspondencia: Dr. R. Teira. Servicio de Enfermedades Infecciosas. Hospital de Basurto. Avda. Montevideo, 18. 48013 Bilbao. España.
, Eva Lizarraldea, Juan M. Santamaríaa, Zuriñe Zuberoa, Pepa Muñoza, Josu Baraiaetxaburuaa, Itziar Olabarríab, Carmen Ezpeletac, José M. Beltrán de Herediab, Ramón Cisternac
a Servicios de Enfermedades Infecciosas
b Hematología
c Microbiología. Hospital de Basurto. Bilbao. España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Introducción

Se están identificando subgrupos con pronóstico diferente entre los pacientes con cáncer e infecciones. Estudios previos han sugerido diferencias relacionadas con el diagnóstico histológico que no han sido demostradas definitivamente.

Métodos

Se revisaron las historias clínicas de los pacientes ingresados con diagnóstico de leukemia aguda o linfoma maligno entre 1988 y 1998. Se calculó la incidencia de bacteriemia para los siguientes subgrupos; leukemia linfoblástica aguda (LLA); leucemia mieloblástica aguda (LMA); LMA con antecedente de anemia refractaria con exceso de blastos (AREB); linfoma maligno de alto grado (LMAG); linfoma maligno de grado intermedio (LMGI); linfoma maligno de bajo grado (LMBG); y linfoma maligno indeterminado (LMI). Se construyeron las curvas de Kaplan-Meier de tiempo hasta el primer hemocultivo positivo y se compararon por el test del rango logarítmico.

Resultados

Se diagnosticaron 244 nuevas leucemias agudas o linfomas en el período estudiado: 62 LMA, 34 LLA, 20 LMA-AREB, 78 LMAG, 7 LMGI, 37 LMBG y 6 LMI. En el momento del cierre del estudio, 44 pacientes estaban vivos, 147 tenían una fecha de fallecimiento conocida y 53 habían sido formalmente perdidos del seguimiento (la mayoría, trasladados para tratamiento paliativo). En 684 hemocultivos se detectaron 51 contaminaciones y 155 aislamientos significativos. De ellos, 74 fueron bacterias grampositivas; 47, gramnegativas; 27, polimicrobianas, y 7, hongos. La incidencia de bacteriemia en casos por 1.000 paciente-días fue 5,80 para la LMA, 5,03 para la LMA-AREB, 1,56 para la LLA, 0,21 para los LMAG y 0,40 para los restantes linfomas. El tiempo hasta el primer hemocultivo positivo fue significativamente menor para la LMA que para cualquier otro grupo; y para la LLA y LMA-AREB que para los linfomas.

Conclusión

Se observó una diferencia en la incidencia de bacteriemia entre grupos definidos histológicamente de pacientes no seleccionados con neoplasias hematológicas.

Palabras clave:
Bacteriemia
Incidencia
Cáncer
Leucemia
Linfoma
Neutropenia
Hemocultivos
Introduction

Subgroups having dissimilar prognoses are being identified among cancer patients with infection. Previous studies have suggested that these differences may be related to the histologic diagnosis, but this issue has not as yet been demonstrated.

Methods

We reviewed the medical records of all patients admitted with acute leukemia (AL) or lymphoma (ML) from 1988 to 1998. Incidence of bacteremia was calculated for the following subgroups: acute lymphocytic leukemia (ALL), acute myelocytic leukemia (AML), AML following refractory anaemia with excess blasts (AML-RAEB), high-grade ML (HGML), intermediate-grade ML (IGML), low-grade ML (LGML) and indeterminate ML (IML). Kaplan-Meier curves of time to the first positive blood culture were constructed and compared by means of log-rank test.

Results

In the period covered there were 244 new diagnoses of AL or ML: 62 AML, 32 ALL, 20 AML-RAEB, 78 HGML, 7 IGML, 37 LGML and 6 IML. At the end of the study period, 44 patients were alive, 147 were known to have died at a certain date and 53 had been formally lost to follow-up (most of them, transferred for hospice care). Among 684 blood cultures, there were 51 contaminations and 155 significant isolates. Among the latter, gram-positive bacteria were isolated in 74 and gram-negative bacteria in 47; in 27 cases more than 1 bacterial species were recovered. Fungi were isolated in 7 cases. The incidence of bacteremia expressed as cases per 1000 patient-days was 5.80 for AML, 5.03 for AML-RAEB, 1.56 for ALL, 0.21 for HGML and 0.40 for the remaining ML. Time to the first positive blood culture was significantly shorter for AML than for any other group, and was shorted for ALL and AML-RAEB than for ML.

Conclusion

Differences in the incidence of bacteremia were observed among histologically-defined groups of unselected patients with hematologic malignancies.

Key words:
Bacteremia
Incidence
Cancer
Leukemia
Lymphoma
Neutropenia
Blood cultures
El Texto completo está disponible en PDF
Bibliografía
[1.]
P. Anderlini, M. Luna, H.M. Kantarjian, S. O’Brien, S. Pierce, M.J. Keating, et al.
Causes of initial remission induction failure in patients with acute myeloid leukaemia and myelodysplastic syndromes.
Leukaemia, 10 (1996), pp. 600-608
[2.]
N. Funai, Y. Shimamoto, O. Tokunaga, W. Sugihara, M. Yamaguchi.
Ten-year survey of incidence of infection as a cause of death in hematologic malignancies: Study of 90 studied causes.
Acta Haematol, 93 (1995), pp. 25-30
[3.]
J. Salonen, J. Nikoskelainen.
Lethal infections in patients with haematological malignancies.
Eur J Haematol, 51 (1993), pp. 102-108
[4.]
European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Co-operative and the National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination therapy for fever in granulocytopenic cancer patients.
J Infect Dis, 163 (1991), pp. 951-958
[5.]
P.J. Johansson, E. Sternby, B. Ursing.
Septicemia in granulocytopenic patients: A shift in bacterial etiology.
Scand J Infect Dis, 24 (1992), pp. 357-360
[6.]
W.T. Hughes, D. Armstrong, G.P. Bodey, A.E. Brown, J.E. Edwards, R. Feld, et al.
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever.
Clin Infect Dis, 25 (1997), pp. 551-573
[7.]
C. Viscoli, P. Bruzzi, E. Castagnola, L. Boni, T. Calandra, H. Gaya, et al.
Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Co-operative Group (IATCG) of the European Organisation for Research and Treatment of Cancer (EORTC).
Eur J Cancer, 30A (1994), pp. 430-437
[8.]
B.E. De Pauw, F. Meunier.
Infections in patients with acute leukaemia and lymphoma.
Principles and Practice of Infectious Diseases (5thed), pp. 3090-3102
[9.]
J.M. Bennett, D. Catovsky, M.T. Daniel, G. Faldrin, D.A.G. Galton, M. Gralnick, et al.
Proposals for the classification of acute leukaemias: French-American-British (FAB) co-operative group.
Br J Haematol, 33 (1976), pp. 451-458
[10.]
The non-Hodgkin’s lymphoma pathologic classification project: National Cancer Institute study of classification of non-Hodgkin’s lymphomas. Summary and description of a working formulation for clinical usage.
Cancer, 49 (1982), pp. 2112-2135
[11.]
N.L. Harris, E.S. Jaffe, H. Stein, P.M. Banks, J.K. Chan, M.L. Cleary, et al.
A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group.
Blood, 84 (1994), pp. 1361-1392
[12.]
K.G. Lucas, A.E. Brown, D. Armstrong, D. Chapman, G. Heller.
The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis.
Cancer, 77 (1996), pp. 791-798
[13.]
S. Spanik, E. Kukuckova, P. Pichna, S. Grausova, I. Krupova, V. Rusnakova, et al.
Analysis of 553 episodes of monomicrobial bacteraemia in cancer patients: Any association between risk factors and outcome to particular pathogen?.
Support Care Cancer, 5 (1997), pp. 330-333
[14.]
S. Rintala.
Incidence and clinical significance of positive blood cultures in febrile episodes of patients with hematological malignancies.
Scand J Infect Dis, 26 (1994), pp. 77-84
[15.]
A. Cometta, S. Zinner, R. De Bock, T. Calandra, H. Gaya, J. Klastersky, et al.
Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer.
Antimicrob Agents Chemother, 39 (1995), pp. 445-452
[16.]
A. Cometta, T. Calandra, H. Gaya, S.H. Zinner, R. De Bock, A. Del Favero, et al.
Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer.
Antimicrob Agents Chemother, 40 (1996), pp. 1108-1115
[17.]
M.C. Escande, R. Herbrecht.
Prospectice study of bacteremia in cancer patients. Results of a French multi-centre study.
Support Care Cancer, 6 (1998), pp. 273-280
[18.]
E. González Barca, A. Fernández-Sevilla, J. Carratalá, A. Grañena, F. Gudiol.
Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution.
Eur J Clin Microbiol Infect Dis, 15 (1996), pp. 291-296
[19.]
S. Spanik, J. Sufliarsky, J. Mardiak, D. Sorkovska, J. Trupl, A. Kunova, et al.
Predictors of mortality in bacteremic cancer patients: Retrospective analysis of 64 deaths occurring among 262 bacteremic episodes.
Support Care Cancer, 6 (1998), pp. 291-294
[20.]
S. Spanik, J. Trupl, A. Kunova, R. Botek, D. Sorkovska, E. Grey, et al.
Viridans streptococcal bacteraemia due to penicillin-resistant and penicillin-sensitive streptococci: Analysis of risk factors and outcome in 60 patients from a single cancer centre before and after penicillin is used for prophylaxis.
Scand J Infect Dis, 29 (1997), pp. 245-249
[21.]
G.P. Bodey, M. Buckley, Y.S. Sathe, E.J. Freireich.
Quantitative relationships between circulating leukocytes and infection in patients with acute leukaemia.
Ann Intern Med, 64 (1966), pp. 328-340
[22.]
J.A. Talcott, R. Finberg, R.J. Mayer, L. Goldman.
The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation.
Arch Intern Med, 148 (1988), pp. 2561-2568
[23.]
J.A. Talcott, R.D. Siegel, R. Finberg, L. Goldman.
Risk assessment in cancer patients with fever and neutropenia: A prospective, two-centre validation of a prediction rule.
J Clin Oncol, 10 (1992), pp. 316-322
[24.]
L.S. Elting, E.B. Rubenstein, K.V.I. Rolston, G.P. Bodey.
Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials.
Clin Infect Dis, 25 (1997), pp. 247-259
[25.]
K.V.I. Rolston, P. Berkey, G.P. Bodey, E.J. Anaissie, N.M. Khardori, J.H. Joshi, et al.
A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.
Arch Intern Med, 152 (1992), pp. 283-291
[26.]
I. Hann, C. Viscoli, M. Paesmans, H. Gaya, M. Glauser.
and the International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organisation for Research and Treatment of Cancer (EORTC). A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies.
Br J Hematol, 99 (1997), pp. 580-588
[27.]
J. Klastersky, M. Paesmans, E. Rubenstein, M. Boyer, L. Elting, L. Feld, et al.
for the Study Section on Infections of MASCC (Multinational Association for Supportive Care in Cancer). The MASCC risk-index: A multinational scoring system to predict low-risk febrile neutropenic cancer patients.
J Clin Oncol, 18 (2000), pp. 3038-3051
[28.]
W.V. Kern, A. Cometta, R. De Bock, J. Langenaeken, M. Paesmans, H. Gaya.
for the International Antimicrobial Therapy Co-operative Group of the European Organisation for Research and Treatment of Cancer. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy.
N Engl J Med, 341 (1999), pp. 312-318
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.eimc.2024.08.008
No mostrar más